JOHNSON & JOHNSON (JNJ) Factsheet
Earnings-call transcript: none · IR deck: cataloged — watch a real agent read these end-to-end →
JOHNSON & JOHNSON (JNJ) Stock Analysis
Analysis from 10-Q filed 2026-10-21. Data as of Q3 2026.
Overall Grade: F (Concerning)
Grade F (Concerning). ROIC 17.6%. FCF margin 20.7%. D/E 0.5x. Source: 10-Q filed 2026-10-21.
| Metric | Value | Context |
|---|---|---|
| ROIC | 17.6% | Solid returns |
| FCF Margin | 20.7% | Strong cash generation |
| Debt/Equity | 0.5x | Moderate leverage |
ROIC 17.6% — Top 25% of sector peers. FCF margin 20.7% — Top 25%.
Explore JOHNSON & JOHNSON: Earnings History | Overview
Programmatic access: Available via MCP at mcp.metricduck.com. Tools for JNJ: get_company_overview, get_filing_index (lens: debt_stress, management_outlook, risk_trajectory), get_filing_section, get_metric_history, compare_companies, screen_filing_signals.
Profitability: JOHNSON & JOHNSON earns 17.6% ROIC, Top 25% in Healthcare
ROIC TTM 17.6%, sector median -7.7%, Top 25%. DuPont: NOPAT margin 23.3% × asset turnover 0.5x. Gross margin 67.6%. Operating margin 25.7%. Source: 10-Q filed 2026-10-21.
| Metric | JNJ | Rating | Context |
|---|---|---|---|
| Return on Invested Capital (ROIC) | 17.6% | Good | Above sector median of -7.7% |
| Return on Equity (ROE) | 19.6% | Good | Efficient use of shareholder equity |
| Gross Margin | 67.6% | Excellent | Strong pricing power |
| Operating Margin | 25.7% | Excellent | Efficient operations |
Cash Flow: JOHNSON & JOHNSON generates $20.6B FCF at 20.7% margin, positive NaN/8 quarters
FCF TTM $20.6B. FCF margin 20.7%, Top 25%. OCF/Net income 1.6x. Positive FCF in NaN/8 trailing quarters. Source: 10-Q filed 2026-10-21.
| Metric | JNJ | Rating | Context |
|---|---|---|---|
| Free Cash Flow Margin | 20.7% | Excellent | Excellent cash conversion |
| Free Cash Flow (TTM) | $20.6B | Good | Positive cash generation |
| OCF/Net Income | 1.6x | Excellent | High earnings quality |
| FCF Consistency (8Q) | N/A | Warning | Variable cash flow |
Balance Sheet: JOHNSON & JOHNSON at 0.5x leverage, 25.9x interest coverage
Debt/Equity 0.5x. Total debt $44.7B, cash & investments $17.2B. Interest coverage 25.9x. Source: 10-Q filed 2026-10-21.
| Metric | JNJ | Rating | Context |
|---|---|---|---|
| Debt to Equity | 0.5x | Good | Moderate leverage |
| Net Cash Position | $-27.4B | Warning | Net debt position |
| Interest Coverage | 25.9x | Excellent | Comfortable debt service |
Valuation: JOHNSON & JOHNSON trades at 42.4x earnings
P/E 42.4x. EV/Sales 7.1x. FCF yield 3.0%. Dividend yield 1.9%. Source: 10-Q filed 2026-10-21.
| Metric | JNJ | Rating | Context |
|---|---|---|---|
| P/E Ratio | 42.4x | Adequate | Premium valuation |
| EV/Sales | 7.1x | Adequate | Growth premium priced in |
| FCF Yield | 3.0% | Adequate | Lower cash yield |
| Dividend Yield | 1.9% | Adequate | Growth focus over income |
Capital Allocation: JOHNSON & JOHNSON returns 3.0% shareholder yield, reducing shares 0.1% YoY
Total shareholder yield 3.0% (div 1.9% + buyback 1.2%). Share count -0.1% YoY. Capital returned $20.6B TTM. Source: 10-Q filed 2026-10-21.
| Metric | JNJ | Rating | Context |
|---|---|---|---|
| Total Shareholder Yield | 3.0% | Good | Dividend + buyback yield combined |
| Buyback Yield | 1.2% | Adequate | Minimal buyback activity |
| Share Count Change (YoY) | -0.1% | Adequate | Net share reduction (accretive) |
| Total Capital Returned (TTM) | $20.6B | Good | Dividends + buybacks returned to shareholders |
Sector Rankings
| Metric | Value | Percentile | vs Median |
|---|---|---|---|
| Return on Invested Capital (ROIC) | 17.6% | Top 25% | - |
| Free Cash Flow Margin | 20.7% | Top 25% | 6.8x above |
| Gross Margin | 67.6% | Top 50% | 1.1x above |
| Operating Margin | 25.7% | Top 25% | - |
| Return on Equity (ROE) | 19.6% | Top 25% | - |
| P/E Ratio | 42.4x | N/A | - |
Financial Scorecard
| Metric | JNJ | Rating | Sector Context |
|---|---|---|---|
| Return on Invested Capital (ROIC) | 17.6% | Good | Top 25% of sector (median: -7.7%) |
| Free Cash Flow Margin | 20.7% | Excellent | Top 25% of sector (median: 3.0%) |
| Gross Margin | 67.6% | Excellent | Top 50% of sector (median: 63.8%) |
| Debt to Equity Ratio | 54.8% | Good | Moderate leverage |
| P/E Ratio (Price-to-Earnings) | 42.4x | Adequate | High expectations priced in |
| Free Cash Flow Yield | 3.0% | Adequate | Moderate yield |
Frequently Asked Questions
Q: What is JOHNSON & JOHNSON's Return on Invested Capital (ROIC)?
JOHNSON & JOHNSON (JNJ) has a trailing twelve-month Return on Invested Capital (ROIC) of 17.6%. The 8-quarter median ROIC is 17.1% with a improving trend. Sector median -7.7%. Source: 10-Q filed 2026-10-21.
Q: What is JOHNSON & JOHNSON's Free Cash Flow Margin?
JOHNSON & JOHNSON (JNJ) has a free cash flow margin of 20.7%, generating $20.6 billion in free cash flow over the trailing twelve months. Source: 10-Q filed 2026-10-21.
Q: What is JOHNSON & JOHNSON's P/E ratio and how does it compare to peers?
JOHNSON & JOHNSON (JNJ) trades at a P/E ratio of 42.4x, which is above the sector median of N/A. EV/Sales 7.1x. FCF yield 3.0%. Source: 10-Q filed 2026-10-21.
Q: Does JOHNSON & JOHNSON pay a dividend?
JOHNSON & JOHNSON (JNJ) currently pays a dividend yield of 1.9%. Total shareholder yield (dividend + buybacks) 3.0%. Source: 10-Q filed 2026-10-21.
Q: How much debt does JOHNSON & JOHNSON have?
JOHNSON & JOHNSON (JNJ) has a debt-to-equity ratio of 0.5x with total debt of $44.7 billion. Interest coverage 25.9x. Net debt $27.4 billion. Source: 10-Q filed 2026-10-21.
Q: What is JOHNSON & JOHNSON's revenue and earnings growth?
JOHNSON & JOHNSON (JNJ) grew revenue by 7.8% year-over-year. EPS -36.4% YoY. Source: 10-Q filed 2026-10-21.
Q: Is JOHNSON & JOHNSON buying back stock?
JOHNSON & JOHNSON (JNJ) repurchased $7.9 billion of stock over the trailing twelve months. This represents a buyback yield of 1.2%. Share count -0.1% YoY. Source: 10-Q filed 2026-10-21.
Q: How does JOHNSON & JOHNSON compare to competitors in Healthcare?
Compared to other companies in Healthcare, JOHNSON & JOHNSON (JNJ) shows: ROIC 17.6%, sector median -7.7% (Top 25%). FCF margin 20.7%, sector median 3.0% (Top 25%). Gross margin 67.6%, 3.7pp above sector median. These rankings are based on MetricDuck's analysis of all Healthcare companies with available SEC filings.
Q: What warning signs should I watch for with JOHNSON & JOHNSON?
No quantitative warning flags fired for JOHNSON & JOHNSON (JNJ) on margin trend, FCF trend, ROIC trend, or leverage thresholds. Source: 10-Q filed 2026-10-21.
Data Source: Data sourced from 10-Q filed 2026-10-21. TTM metrics as of Q3 2026.
Methodology: Financial metrics calculated from SEC 10-K and 10-Q filings using standardized formulas. Sector comparisons use peer group based on SIC code.
Scope: This analysis covers SEC filing fundamentals — profitability, cash flow, balance sheet, and valuation metrics. For analyst estimates and price targets, consult sell-side research.
This analysis is for informational purposes only and does not constitute investment advice.
Data provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use. iex.io/legal/hist-data-terms